Incyte Corporation vs Symbotic Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Symbotic Inc trades at $42 (market cap $5.41B). The key difference: Incyte Corporation is far larger — about 4.5× Symbotic Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SYM | |
|---|---|---|
Market Cap | $24.54B | $5.41B |
Sector | Health | Technology |
52-Week High | $129.93 | $87.30 |
52-Week Low | $81.61 | $38.57 |
Enterprise Value | $20.04B | $3.67B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →